Access here alternative investment news about Who Panel To Review Covaxin Data For Emergency-use Listing On October 5

Who Panel To Review Covaxin Data For Emergency-use Listing On October 5

by moneycontrol.com posted 1month ago 1 views
Inclusion of indigenously developed Covaxin in the WHO list will boost global acceptance of the Covid-19 vaccine. : Pre-configured baskets of stocks & ETFs that you can invest in with a single click. Developed by hedge funds, global asset management companies, experienced wealth management firms and portfolio managers. Curated markets data, exclusive trading recommendations, Independent equity analysis & actionable investment ideas A World Health Organization expert panel is scheduled to review the clinical trial data of Bharat Biotech’s Covid-19 vaccine Covaxin on October 5, according to the committee’s agenda for the meeting.

In this article

No tags related to this article.